SB 222200, >=98% (HPLC), solid

SB 222200, >=98% (HPLC), solid

Application

The pharmacodynamics profile of SB 222200 enables its use as a tool to study physiological and pathophysiological roles of NK-3 receptor in CNS-modulated behaviors.

Biochem/physiol Actions

Non-peptide NK3 tachykinin receptor antagonist.

SB 222200 is a 2-phenyl-4-quinolinecarboxamides and a selective, reversible and competitive antagonist of human NK-3 receptor that effectively crosses the blood-brain barrier. It inhibits the NK-3 receptor-induced miosis or pupil constriction in conscious rabbits.1,2

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from GlaxoSmithKline

Packaging

10, 50 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Form Assay Price Quantity
3573912 SB 222200, >=98% (HPLC), solid light yellow 100 MQNYRKWJSMQECI-QFIPXVFZSA-N 1S/C26H24N2O/c1-3-22(19-12-6-4-7-13-19)28-26(29)24-18(2)25(20-14-8-5-9-15-20)27-23-17-11-10-16-21(23)24/h4-17,22H,3H2,1-2H3,(H,28,29)/t22-/m0/s1 SIGMA-ALDRICH solid ≥98% (HPLC)
£321.75 (exc VAT) per 10MG
-
+
3573913 SB 222200, >=98% (HPLC), solid light yellow 100 MQNYRKWJSMQECI-QFIPXVFZSA-N 1S/C26H24N2O/c1-3-22(19-12-6-4-7-13-19)28-26(29)24-18(2)25(20-14-8-5-9-15-20)27-23-17-11-10-16-21(23)24/h4-17,22H,3H2,1-2H3,(H,28,29)/t22-/m0/s1 SIGMA-ALDRICH solid ≥98% (HPLC)
£819.00 (exc VAT) per 50MG
-
+